• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT LABORATORIES TOTAL BILIRUBIN; DIAZO COLORIMETRY, BILIRUBIN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT LABORATORIES TOTAL BILIRUBIN; DIAZO COLORIMETRY, BILIRUBIN Back to Search Results
Model Number 6L45-21
Medical Device Problem Code Low Test Results (2458)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 09/28/2021
Type of Reportable Event Malfunction
Event or Problem Description
The customer observed a falsely decreased total bilirubin result for a pregnant female patient.The following data was provided (customer¿s reference range is 0.3-1.2 mg/dl): initial result was 0.2, repeat was 0.4 mg/dl.There was no impact to patient management reported.
 
Additional Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.All available patient information was included.Additional patient details are not available.
 
Additional Manufacturer Narrative
The complaint investigation for falsely decreased total bilirubin results, while using total bilirubin reagent, included a review of data and information provided by the customer, ticket trending review, labeling review, and device history record review.Trending review determined no related trend for falsely elevated results for the product.Return testing was not completed as returns were not available.A review of the product labeling concluded that the issue is sufficiently addressed.Manufacturing documentation for the likely cause list number were reviewed and did not identify any issues.File samples were not tested, as the repeat test at the customer site produced an acceptable result.In addition, the quality control was acceptable during the falsely depressed result.This indicates the assay is performing as expected.Based on all available information and abbott diagnostics' complaint investigation, no systemic issue or product deficiency with the total bilirubin reagent, list number 06l45, was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TOTAL BILIRUBIN
Common Device Name
DIAZO COLORIMETRY, BILIRUBIN
Manufacturer (Section D)
ABBOTT LABORATORIES
1915 hurd drive
irving TX 75038
Manufacturer (Section G)
ABBOTT LABORATORIES
1915 hurd drive
irving TX 75038
Manufacturer Contact
siobhan wright
lisnamuck
post market surveillance
longford, IL N39 E-932
2246682940
MDR Report Key13047845
Report Number3016438761-2021-00528
Device Sequence Number19228638
Product Code CIG
UDI-Device Identifier00380740011369
UDI-Public00380740011369
Combination Product (Y/N)N
Initial Reporter StateNY
Initial Reporter CountryUS
PMA/510(K) Number
K121985
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Health Professional
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 01/13/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model Number6L45-21
Device Catalogue Number06L45-21
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Follow-Up
Initial Date Received by Manufacturer 11/24/2021
Supplement Date Received by Manufacturer01/04/2022
Initial Report FDA Received Date12/20/2021
Supplement Report FDA Received Date01/13/2022
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
ARC C8 PROC MOD, 01G06-11, C803700.; ARC C8 PROC MOD, 01G06-11, C803700.
Patient SexFemale
-
-